Evoke pharma inc (EVOK)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-1,790

-1,418

-1,628

-2,114

-1,965

-1,760

-1,519

-2,303

-1,982

-308

-5,243

-1,625

-5,052

-1,527

-3,025

-2,970

-3,225

-2,624

-2,735

-3,241

-3,520

-2,919

-3,825

-3,547

-2,955

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

310

318

331

344

378

378

380

387

393

414

475

464

464

408

452

427

418

376

371

384

371

309

303

265

223

Non-cash interest

-

-

-

-

-

-

-

-

-

-

-

-

-

0

100

10

10

10

15

15

15

5

5

42

5

Deferred rent expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

2

3

3

2

2

-1

-8

Change in fair value of warrant liability

-

-

-

-

-

0

0

0

-433

-2,349

1,544

-1,261

3,072

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Prepaid expenses and other assets

-227

-229

631

-143

-142

-109

355

-83

-83

-83

-253

416

-104

-145

-74

-265

-68

-102

219

-141

-73

-62

242

165

-58

Accounts payable and other current liabilities

-298

-

869

-2

-482

-

344

70

-879

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-573

769

743

-275

400

-751

37

37

-314

66

158

68

23

-151

335

659

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-1,686

-1,369

-2,417

-2,229

-2,690

-2,452

-2,504

-2,544

-2,995

-2,520

-3,911

-3,067

-2,000

Payment on bank loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,639

360

Net cash used in operating activities

-1,551

-1,147

-1,059

-1,628

-1,926

-1,248

-1,149

-1,761

-2,817

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Proceeds from issuance of common stock, net

21

306

123

5,039

636

0

1,186

2,886

544

0

56

-2

7,334

-3

0

259

98

404

3,359

734

531

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

7,334

-3

8,668

259

98

404

3,359

734

531

4,500

42

-2,722

-360

Net cash provided by financing activities

21

306

123

5,039

636

0

1,186

2,886

544

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-1,530

-

-

-

-1,290

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

1,125

-2,273

-2,733

-2,143

-2,098

5,647

-1,372

6,250

-1,970

-2,591

-2,047

855

-1,809

-2,463

1,979

-3,869

-5,789

-2,361

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

0

44

63

62

62

63

63

41

0

0

26

32

Non-cash financing activities
Deferred financing costs paid in prior year

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

137

-

-

-

-

Reclassification of warrant liability to equity due to exercise of warrants

-

-

-

-

-

-

-

-

-

0

0

0

1,399

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of warrant liability to equity due to amendment of warrants

-

-

-

-

-

0

0

0

3,267

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-